Core Viewpoint - The report highlights the performance and holdings of the Fuqua Precision Medical Mixed A Fund, showcasing its strong returns and key stock positions in the healthcare sector [1]. Fund Performance - The latest net value of Fuqua Precision Medical Mixed A is 3.2727 yuan, with a growth of 0.62% - The fund's one-month return is 18.98%, ranking 20 out of 2331 in its category - Over the past six months, the return is 35.63%, ranking 14 out of 2295 - Year-to-date, the return stands at 46.87%, ranking 12 out of 2306 [1]. Fund Holdings - The top ten stock holdings of Fuqua Precision Medical Mixed A account for a total of 69.71%, with the following key positions: - Baillie Gifford (9.66%) - Haisco (9.65%) - Kelun Pharmaceutical (9.10%) - Huatai Medical (9.05%) - Zai Lab (7.84%) - Hansoh Pharmaceutical (5.95%) - Innovent Biologics (5.29%) - Sinovac Biotech (5.11%) - BeiGene (4.91%) - Zhaoke Pharmaceutical (3.15%) [1]. Fund Manager Background - Zhao Wei, the fund manager, has a master's degree and extensive experience in the pharmaceutical and investment sectors - Previous roles include positions at GlaxoSmithKline, GF Securities, and China Merchants Fund Management - Zhao has managed various funds focused on healthcare and small-cap investments before joining Fuqua Fund Management in March 2021 [2].
6月10日富国精准医疗混合A净值增长0.62%，今年来累计上涨46.87%
Sou Hu Cai Jing·2025-06-10 12:00